risk sharing

A study to be presented at the BMT Tandem Meetings found no difference in OS for patients aged 55-64 years compared with those aged 65 years and older with non-Hodgkin lymphoma who underwent alloHCT.
A recent study found that a biosimilar provides improved outcomes without increased risk of toxicity for patients with DLBCL and treatment-induced neutropenia.
The National Comprehensive Cancer Network has updated their guideline for breast cancer risk reduction, including significant changes to the section on components of risk/benefit assessment and counseling.
According to a recent research letter, the risk for breast cancer morbidity differs by subtype in survivors of Hodgkin lymphoma treated with radiotherapy.
In recent years, there has been a significant increase in hospitalizations, readmissions, and deaths due to immune-related adverse events from immune checkpoint inhibitors, according to a presentation at the ASCO-SITC Clinical Immuno-Oncology Symposium.
A recent study summarized the available evidence on adverse events associated with checkpoint inhibitors in patients with cancer and preexisting autoimmune disease.
Higher scores on a multi-biomarker disease activity system are associated with hospital infection, myocardial infarction, and coronary heart disease events in older patients with rheumatoid arthritis.
A recent study examined whether a history of Epstein-Barr virus positivity or immunosuppression affects outcomes in patients with a type of B-cell lymphoma.
Adding a specific class of inhibitors to multiple myeloma treatment may not improve survival outcomes, but it does reduce overall pain and vertebral fractures.
The treatment of mantle cell lymphoma carries a significant economic burden in the real-world setting, according to research presented at the ASH Annual Meeting & Exposition.